We are committed to bringing meaningful therapeutic options to patients, healthcare providers, and payers. We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including a FDA approved non-opioid therapy for use in the acute care setting.
On February 20, 2020, the FDA approved ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. Our product pipeline contains valuable therapeutic candidates for patients and healthcare providers in acute care settings.